Kelun Pan

Introduction Breast cancer remains the most common malignancy among women worldwide and continues to pose a substantial global public health challenge.1 Human epidermal growth factor receptor 2 (HER2), encoded by the ERBB2 gene, is overexpressed or amplified in approximately 15%–20% of breast cancer patients.2 This molecular alteration is associated with increased tumor aggressiveness, poorer prognosis, and response to specific targeted therapies.3 The introduction of HER2-targeted agents,...

Back to Journals » Journal of Inflammation Research » Volume 19 Authors Liang H, Pan K, Liang X, Wang J, Xie X, Wan N, Lin J Received 15 October 2025 Accepted for publication 7 January 2026 Published 17 January 2026 Volume 2026:19 Pages 1—13 DOI https://doi.org/10.2147/JIR.S573858 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Alberto Caminero Huikai Liang,1,2,* Kelun Pan,1,* Xinlan Liang,3,* Jiayi...

References Yu X, Wan Y, Sippel R, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg. 2011;254(4):653–60. Article PubMed Google Scholar Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol. 2018;44(3):307–15. Article CAS PubMed Google Scholar Sobin L. Histological typing of thyroid tumours. Histopathology. 1990;16(5):513.